Autopsy report · NCT01583686
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Cause of deathSlow enrollment
“Study terminated due to slow/insufficient accrual.”
Life of this trial
- Ran for about 6 years 7 months before it stopped.
- 15 participants enrolled.
- Results were posted on the registry 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Cervical Cancer; Pancreatic Cancer; Ovarian Cancer; Mesothelioma; Lung Cancer
- Interventions
- Fludarabine; Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL); Cyclophosphamide; Aldesleukin
- Participants
- 15
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
“Study terminated due to slow accrual.” - LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
“Study was terminated due to slow accrual.” - Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
“Study terminated due to low accrual.” - Effectiveness of Lumbar Fusion When NanOss Bioactive Is Used With Posterolateral Gutter Fusions
“Study was terminated due to slow accrual rate.” - Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
“Study was terminated due to poor accrual”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.